Novartis AG ADR (NVS)vsZEN Graphene Solutions Ltd (ZTEK)
NVS
Novartis AG ADR
$155.41
+0.19%
HEALTHCARE · Cap: $296.54B
ZTEK
ZEN Graphene Solutions Ltd
$0.49
-1.91%
HEALTHCARE · Cap: $51.37M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 6000451% more annual revenue ($56.58B vs $942,880). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold49
out of 100
Grade: D+
ZTEK
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.7%
Fair Value
$91.58
Current Price
$155.41
$63.83 premium
Margin of Safety
+86.9%
Fair Value
$4.99
Current Price
$0.49
$4.50 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Revenue surging 73.1% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -65.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : ZTEK
The strongest argument for ZTEK centers on Revenue Growth, Debt/Equity. Revenue growth of 73.1% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : ZTEK
The primary concerns for ZTEK are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
NVS profiles as a declining stock while ZTEK is a hypergrowth play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
ZTEK is growing revenue faster at 73.1% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 23/100), backed by strong 23.9% margins. ZTEK offers better value entry with a 86.9% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →ZEN Graphene Solutions Ltd
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
ZEN Graphene Solutions Ltd (ZTEK) is an innovative leader in the materials technology sector, specializing in the extraction and commercialization of high-purity graphene derived from natural graphite. Through its proprietary techniques, ZTEK is poised to impact numerous industries, including energy storage, environmental remediation, and advanced manufacturing, offering cutting-edge graphene solutions. The company’s strategic focus on sustainability, underpinned by significant research and development initiatives, enhances its competitive edge in the rapidly expanding graphene market. As ZTEK leverages emerging opportunities and continues to advance its technological capabilities, it is well-positioned to deliver substantial long-term value for investors in the context of rising global demand for innovative and advanced materials.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?